Jefferies Maintains Buy on Denali Therapeutics, Raises Price Target to $45
Denali Therapeutics +6.73%
Denali Therapeutics DNLI | 24.89 | +6.73% |
Jefferies analyst Michael Yee maintains Denali Therapeutics (NASDAQ:
DNLI) with a Buy and raises the price target from $40 to $45.